| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8629750 | Diabetes Research and Clinical Practice | 2018 | 15 Pages |
Abstract
SMBG seems to lead to a slightly better glycemic control in the short term in patients with T2D. Patients decompensated at baseline appear to have the greatest benefit. PROSPERO register: CRD42016033558.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Rafael Vaz Machry, Dimitris Varvaki Rados, Guilherme Ribeiro de Gregório, Ticiana Costa Rodrigues,